Dan Estes

Dan Estes has served as a member of their board of directors since June 2021. Dr. Estes is a General Partner on the Frazier Life Sciences team and has been involved with investing in and building many of Frazier’s biopharmaceutical portfolio companies over the past 11 years. Dr. Estes joined Frazier Healthcare Partners in 2011 and focuses on investments in both development-stage and commercial-stage pharmaceutical companies. He has led Frazier’s investments in, and serves on the boards of, Arcutis (NASDAQ: ARQT, co-founder), Hawkeye Therapeutics, Lengo Therapeutics, Inipharm, Sudo Biosciences and Cirius Therapeutics. He previously served on the boards of Semnur Pharmaceuticals (acquired by Scilex) and Sierra Oncology (NASDAQ: SRRA) and led Frazier’s investment in Tarsus Pharmaceuticals (NASDAQ: TARS).

Dr. Estes has also been involved in Frazier’s investments in Acerta Pharma BV (acquired by AstraZeneca), Tobira Therapeutics (acquired by Allergan), Ignyta (acquired by Roche), Iovance (NASDAQ: IOVA), Vaxcyte (NADAQ: PCVX), and PreCision Dermatology (acquired by Valeant). Prior to joining Frazier, Dr. Estes was a management consultant with McKinsey & Company’s healthcare practice, where he led teams that advised leading global pharmaceutical and biotechnology companies on R&D strategy and business development strategy. He received his PhD in Biomedical Engineering from the University of Michigan and holds a BS in Electrical Engineering from Stanford University, where he is a member of Tau Beta Pi. In 2018, Dr. Estes was named a “40-and-under Silicon Valley biotech investing star” by Business Insider.